Prevent IDIQ mato RFP

Planning 30 Days for RFP open period. Questions will be due by 18 Jan 2023, Not Later Than (NLT) 3:00 PM Eastern Time.
The overall objective of the current acquisition, designated as the PREVENT Cancer Preclinical Drug Development
Program, is to provide a structured approach to drug and vaccine development, from discovery to the clinic. To
achieve these goals, this acquisition is broken out into three separate multiple-award Indefinite Delivery Indefinite
Quantity (IDIQ) pools:
PREVENT Efficacy Pool:
The Preclinical Efficacy and Intermediate Endpoint Biomarkers IDIQ contracts will encompass the continued
evaluation of the efficacy of potential chemopreventive and immunopreventive regimens, and the identification of
pharmacodynamic and/or efficacy biomarkers which will enhance the development of these regimens for clinical trials.
Resources from these contracts will be used to support development of several candidate cancer preventive agents.
PREVENT CGMP Pool:
The PREVENT Preclinical Services for Biopharmaceutical Product Development and Manufacturing encompasses
four main technical task areas: (1) product development planning and evaluation; (2) analytical assay development
and product characterization; (3) process development and related activities; and (4) CGMP manufacturing,
related activities and documentation, as described in detail in the Statement of Work. The key objective of the
PREVENTCGMP pool is to provide preclinical product and CGMP manufacturing support for candidate cancer
preventive vaccines for preclinical and clinical testing.
PREVENT Toxicology and Pharmacology Pool:
The PREVENT Preclinical Cancer Program: Toxicology and Pharmacology Testing IDIQ contracts will continue evaluation of the pharmacological and toxicological effects of potential cancer preventative agents. Resources from these contracts will be used to support development of several candidate cancer preventive agents.